Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy

• Published in: Frontiers in oncology Vol. 11; p. 782682
• Main Authors: Zhai, Xiaoqian, Wu, Qiang, Pu, Dan, Yin, Liyuan, Wang, Weiya, Zhu, Daxing, Xu, Feng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05.01.2022
• Subjects: adjuvant targeted therapy; alectinib; ALK fusion; ALK-GCA and EML4-ALK; Oncology; stage IIIB-N2 NSCLC; adjuvant targeted therapy; ALK-GCA and EML4-ALK; stage IIIB-N2 NSCLC; ALK fusion; alectinib

Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLCs) have favorable and impressive response to ALK tyrosine kinase inhibitors (TKIs). However, ALK rearrangement had approximately 90 distinct fusion partners. Patients with different ALK fusions might have distinct responses...